Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Ascentage Pharma Presents Lisaftoclax Clinical Data, Including Oral Report, at ASH 2025
Bridging RRMM Treatment Gaps: Advanced Clinical Strategies Beyond Frontline Failure
Avera Medical Minute: Collaborative Cancer Care Helps Patients Get Treatment Locally
Gallop Oncology Presents New LYT-200 Phase 1b Data at ASH 2025
Avera Medical Minute: Team-Based Cancer Care Helps Patients Receive Local Treatment
Community Unites to Support Volcano Vista Athlete Battling Cancer Courageously
Community Rallies Around Volcano Vista Athlete Courageously Battling Cancer Journey
St. Jude Researchers Discover Promising New Therapeutic Target for Pediatric Leukemia
Mutant UBTF Gene’s Abnormal Transport Signal Drives Aggressive Acute Myeloid Leukemia
DelveInsight 2025 Report: Novel Antiviral Drugs Show Promise in RR-AML
Chronic Lymphocytic Leukemia treatment market shows rising trends, promising future opportunities.
DelveInsight’s 2034 report analyzes B-Cell Chronic Lymphocytic Leukemia Market landscape.
Genes-first and phenotypes-first approaches reveal treatment resistance mechanisms in hematologic ma
Non-coding RNAs serve as predictive biomarkers for Chronic Lymphocytic Leukemia outcomes.
DelveInsight analyzes B-Cell Chronic Lymphocytic Leukemia Market trends through 2034.
ASH 2025 Tip Sheet: Sylvester researchers deliver over 35 oral presentations.
Acute Lymphoblastic Leukemia treatment market shows rising trends, unlocking future opportunities.
Exercise significantly enhances recovery and overall outcomes for stem cell transplant patients.
Sylvester researchers to present over 35 oral sessions at ASH 2025.
Challenging fixed age cut-offs in AML treatment and clinical trial decisions.
Blog shares Josiah’s inspiring story in the Hockey Fights Cancer campaign.
Saskatoon mother writes children’s book about daughter lost to cancer to support others.
CLL advances driven by doublet, triplet regimens and response-adapted treatment strategies.
A cancer survivor reflects on gratitude and renewed perspective during this season.
Acute myeloid leukemia market expected to see significant growth by 2034, DelveInsight reports.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Leukemia & Lymphoma Society Rebrands as Blood Cancer United to Support All Patients
Riddhima Kapoor Sahni Reflects on Leaving Daughter During Rishi Kapoor’s Leukemia Diagnosis
US Chronic Lymphocytic Leukemia Market to Reach $9.1 Billion by 2033
Cytogenetic Treatment Response Predicts Long-Term Survival in Acute Myeloid Leukemia Patients
Chronic Lymphocytic Leukemia Therapeutics Market to Hit $10.3 Billion by 2035
Hong Hyun-hee Pays Tribute to Jeong Se-hyeop: “Rest Peacefully, Free from Pain”
Jeong Se-hyeop Passes Away Following Leukemia Recovery Comeback
Comedian Jeong Se-hyeop Dies One Year After Leukemia Recovery, Return
Study Shows Accelerated Transplants Are Safe for Leukemia Patients
Ziftomenib shows promise in treating relapsed or refractory NPM1-mutant AML.
Managing CLL through evolving approaches and implementing innovative therapeutic strategies effectiv
DelveInsight reveals 2025 T-cell acute lymphoblastic leukemia pipeline and emerging therapies.
Medical students raise over $4,700 supporting classmate fighting leukemia.
Franklin students 'go gold' for 4-year-old cancer survivor.
Evaluating therapeutic strategies within the lymphoma treatment algorithm for optimal outcomes.
Identifying the most effective treatment strategies for managing chronic lymphocytic leukemia.
UNC student shares journey overcoming two separate battles with cancer.
Applying CLL clinical trial successes effectively to real-world treatment practices.
Vaginal myeloid sarcoma: rare extramedullary manifestation of myeloid neoplasm.
Oral leukemia therapies market projected to reach $12.98 billion by 2034.
Five key facts everyone should know about clonal hematopoiesis.
Long Island restaurants support W. Babylon toddler in her fight against leukemia.
Father with cancer in ICE custody denied doctor access, lawsuit claims.
Acute lymphoblastic leukemia market projected to reach $6.98 billion by 2034.
Dual-drug strategy shows promise in targeting acute myeloid leukemia effectively.
John C. Byrd, MD, has been elected to the National Academy of Medicine.
LOWVELO rider with leukemia inspires Charleston community, offering hope through biking.
Chronic Myelomonocytic Leukemia 2025 pipeline highlights innovations by 20+ global leaders.
MYBL2, a cell cycle regulator, represents a unique vulnerability in AML.
Researchers study leukemia survivors linked to Down syndrome for medical insights.
Baltimore family and doctors' teamwork result in young boy's lifesaving transplant.
Pfizer’s pediatric leukemia study shows promise as a potential treatment breakthrough.
Amgen’s pediatric leukemia study reveals promising results and key investor insights.
BeOne Medicines progresses Phase 3 clinical trial advancing leukemia treatment options.
Amgen’s Phase 3 Blinatumomab study shows promise for leukemia treatment investors.
Syndax Pharmaceuticals’ Revumenib study shows promise as a leukemia treatment breakthrough.
Suleika Jaouad looks back 15 years after her leukemia diagnosis.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:‍
The Future of Blood Cancers: Advances Driving Improved Patient Care
Dr. Shadman Discusses Rationale for Evaluating Zanubrutinib Plus Venetoclax in Untreated CLL/SLL
Oncology Social Work Provides Essential Support in Blood Cancer Treatment
Former WWE Champion Claims Roman Reigns’ Leukemia Was Entirely Storyline
Eli Lilly’s Leukemia Medication Demonstrates Promising Results in Clinical Trials
EMA designates OXC-101 as an orphan drug for acute myeloid leukemia.
BH3 mimetics are transforming the treatment landscape of acute myeloid leukemia.
Developing AML prognostic risk model using exosomal genes and immune characteristics.
Blood Cancer Awareness Month highlights upcoming innovations and breakthroughs in biotechnology.
Targeting Nrf2 offers a strategy to overcome chemoresistance in AML.
ACSL5 influences Wnt/β-catenin signaling via palmitoylation in AML prognosis.
Dr. Khan discusses development of second-generation BTK inhibitors in CLL.
Currently recruiting clinical trials for lung, biliary, AML, and small cell cancers.
Local family spreads awareness after losing their child to aggressive leukemia.
Achille Polonara discusses leukemia battle, revealing suicidal thoughts during his struggle.
Silver medalist presents personalized thank-you gift for Leukemia Awareness Month.
Heritage Insurance fulfilled a Disney wish for 3-year-old leukemia survivor.
Jesse Turner inspires 9-year-old leukemia patient with heartfelt bedside serenade.
Case report: Cutaneous mucormycosis in CLL patient on targeted therapy.
Disease: Acute Myeloid Leukemia, specifically relapsed or refractory AML cases.
9-year-old donates stem cells, helping save his father’s life.
Innovative tool may revolutionize diagnosis and treatment of acute leukemia patients.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
AI-powered tool accelerates diagnosis process for acute myeloid leukemia patients.
‍Leukemia therapy market projected to hit \$31.4B by 2032.
‍Leukemia therapy market projected to hit \$31.4B by 2032.
‍Clinical trial offers hope for Micah and future young patients.
‍Dr Khan discusses acalabrutinib’s role in today’s CLL treatment landscape.
‍Study examines molecular, cytogenetic response impact on pediatric CML outcomes.
‍UA Little Rock runner shares inspiring journey of overcoming leukemia battle.
CAR T Therapy in ALL: Clinical Insights, Pipeline, and Emerging Therapies
China’s BRL Prepares to Launch First UCAR-T Trial for Leukemia/Lymphoma
Advancing Supportive Care in Leukemia: Taking the Next Critical Steps
Dr Ghia Discusses Rationale for Testing Pirtobrutinib in Relapsed/Refractory CLL
Cathepsin D Drives Acute Myeloid Leukemia by Upregulating Anti-Apoptotic Proteins
Broadening the Use of Menin Inhibitors in Acute Myeloid Leukemia
Cancer Cells Conceal Within Bone Marrow Fibroblasts to Evade Treatment
Italian Doctors Reject Israel’s Claim, Cite Malnutrition in Palestinian Woman’s Death
Physical Function Strongly Predicts Survival in Older Adults Undergoing Low-Intensity Leukemia Treat
AP Reports Gazan Evacuee’s Death from Starvation, Omits Leukemia Context
Liquid Phase Separation Patterns Serve as Predictors of Pediatric AML Outcomes
Targeting PRDX1 Disrupts Redox Balance, Weakening AML Blasts and Stem Cells
Dr. Scarfò Shares Early Safety Findings of BGB-16673 in R/R CLL/SLL
Dr. Visentin Discusses Sequencing Impact on CLL Treatment Costs
Leukemia Patients Face Increased Infection Risk During Immunoglobulin Replacement Therapy
Acute Myeloid Leukemia Pipeline 2025: Trials, Approvals, MOA, ROA, Companies
Retinoic Acid Disrupts NPM1c/ROS/SENP3/ARF Oncogenic Axis in AML
Davenport Teen Dies After Room Transformation During Leukemia Battle
World’s Most Widely Used Herbicide Now Linked to Leukemia, Tumors
Venetoclax Combined with Ponatinib Treats Asciminib-Resistant Chronic Myeloid Leukemia
CAR T-Cell Therapy Targeting CD84 for Treating AML and T-ALL
Dr. Dorritie Discusses Management of Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia
Retinoic Acid Disrupts NPM1c/ROS/SENP3/ARF Oncogenic Axis in AML

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Are BTK Inhibitors Suitable as First-Line Treatment for Mantle Cell Lymphoma?
‍Frontline ALL: Long-Term Outcomes and Emerging Innovative Treatment Approaches
‍Emerging Treatment Strategies for Managing Patients With Chronic Lymphocytic Leukemia
‍Optimizing Treatment of Ph-Positive ALL Through Targeted Immunotherapy Approaches
IDH-triplet therapy delivers strong outcomes in IDH-mutant AML patients.
Case report: Dual malignancy of RCC and CLL in one node.
Study finds planned C-sections may increase cancer risk in babies.
PhALLCON Study Shows Ponatinib’s Potential in Treating Ph+ ALL
UVA Study Finds Mismatched Stem Cell Transplants Safe for Blood Cancers
Dr. Munir Discusses MAIC Comparing Zanubrutinib and Fixed-Duration Regimen in CLL
AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL
Leukemia Survivor Coca Bernard Launches Coca Strong Run for Awareness.
Philadelphia-Developed Childhood Leukemia Drug Now Saving Young Patients’ Lives.
European Commission Approves Obe-Cel for Adult Relapsed B-Cell ALL.
Dr. Scarfo Discusses Future of BGB-16673 in Relapsed CLL/SLL.
Leukemia Survivor Defies Odds to Conquer the Tour de France.
Evidence-based approaches for selecting frontline therapies in treatment-naive CLL.
Ribosomal protein L5 triggers senescence through p53-p21-pRb, mediating AML relapse.
Fynn Williams, 10, defeats leukemia and receives a heartfelt hero’s welcome.
Dr. Danilov discusses key factors in selecting frontline CLL treatment.
Immunotherapy shown to change bone marrow environment in acute myeloid leukemia.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Dr. Hernandez-Ilizaliturri discusses immunologic changes in CLL with venetoclax.
‍Dr. Burke discusses CLL treatment challenges in community versus academic settings.
‍Continuing ponatinib benefits Ph+ ALL patients lacking early MRD negativity.
‍Dr. Cortese discusses future directions for multiomic venetoclax research in CLL.
ASC2ESCALATE trial explores asciminib dose escalation strategy in CML treatment.
Dr. Munir compares first-line zanubrutinib vs acalabrutinib plus venetoclax efficacy.
Dr. Scarfò shares updated BGB-16673 safety data in relapsed CLL/SLL.
Dr. Ghia discusses Ibrutinib-Venetoclax fixed-duration efficacy in CLL/SLL.
New BTK degrader effective in CLL/SLL despite mutation status.
Further research required to understand Ziftomenib’s mechanism in AML treatment.
New BTK degrader effective in CLL/SLL despite mutation status.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
‍Dr. Bhat Weighs Liso-Cel vs Pirtobrutinib for Relapsed/Refractory CLL
Dr. Ghia Compares CLL OS on Ibrutinib/Venetoclax to Healthy Population
Dr. Jain Addresses Challenges in Defining Venetoclax Failure in CLL Patients
Dr. Shadman Explores Meta-Analysis Value of BTK Inhibitors in CLL
Dr. Shadman Outlines Meta-Analysis Framework for BTK Inhibitors in CLL
Dr. Cortese Explores Ways Venetoclax May Improve CLL Outcomes
Understanding and Managing the Challenges of Immunotherapy in Treating ALL
Dr. Winter explains treatment history’s role in Richter Transformation development.
Dr. Bhat discusses BTK degraders and bispecific antibodies for R/R CLL.
Dr. Bhat discusses the limitations of current therapies for double-refractory CLL.

‍The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Dr. Awan Discusses Patient Factors for CAR T-Cell Eligibility in CLL
Revumenib-Based Therapy For Acute Myeloid Leukemia
First-line Ponatinib + Blinatumomab in Adults With Ph+ Acute Lymphoblastic Leukemia
Dr. Cortese discusses multiomic evaluation of immunologic changes in CLL post-Venetoclax.


The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Panelists discuss the role of venetoclax-ibrutinib across various patient populations.
Asciminib Shows Better Safety and Tolerability Than TKIs in Newly Diagnosed CML
Comparing Venetoclax-Ibrutinib, Venetoclax-Obinutuzumab, and BTK Inhibitor Treatment Options
Exploring Novel BCL2 and BTK Inhibitor Combinations in Frontline CLL Therapy.
Managing CLL with TP53 Mutations or del(17p): Strategies and Guidelines.
Applying Menin Inhibitor Therapy for Patients With Relapsed Acute Myeloid Leukemia.
Approaching BTK Inhibitor Resistance and Mutations in Chronic Lymphocytic Leukemia.Treatment Options and Considerations for Progression on BTK Inhibitors
BTK Inhibitor Progression: Exploring Treatment Options and Key Considerations
New Therapies and Future Approaches in Relapsed/Refractory CLL
Dr. Cortese on Venetoclax's Role in Repairing the Immune Synapse in CLL
Insights and Future Perspectives in CLL Management

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org

Greetings from MyCancerHaven!

We wanted to update you on our recent activities.

Here are the latest posts last month:
Menin Inhibitors in Treatment of AML
Customized treatment approaches for older patients with secondary AML.
Implications of ESMO Guidelines for IGHV-Mutated versus Unmutated CLL Patients
Recent Guideline Updates on Frontline Management of Chronic Lymphocytic Leukemia
Dr. Awan discusses CAR T-Cell Therapy's impact on CLL treatment.
Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated Chronic Lymphocytic Leukemia.
Dr. Niemann discusses the investigation of ibrutinib plus venetoclax in CLL.
Dr. Alencar discusses the rationale for investigating BTK degraders in CLL.
Time-limited Venetoclax-Obinutuzumab therapy: rationale and supporting data.
Clinical insights and real-world evidence shaping treatment decisions and outcomes.
Dr. Ghia discusses potential future roles for ibrutinib plus venetoclax in CLL.

The News and Tweets never stop flowing, so follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok, or Join for Free.

Sincerely,

– The MyCancerHaven Team

Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org